Introduction
Intracranial arterial calcification (IAC) is a significant risk factor for cerebral infarction and serves as a critical biomarker for intracranial artery stenosis, particularly within Asian populations. While IAC can be visualized through brain computed tomography angiography (CTA), there is a clinical need for accessible blood-based biomarkers to predict its severity and patient prognosis.
Gamma-glutamyl transferase (GGT), an enzyme traditionally associated with liver function and alcohol consumption, has recently emerged as a potential mediator of cardiovascular disease. GGT facilitates the breakdown of extracellular glutathione, a process that can generate reactive oxygen species (ROS). These pro-oxidants contribute to oxidative stress, promoting the oxidation of low-density lipoproteins (LDL) and accelerating atherosclerotic plaque formation and arterial hardening. This study investigates the relationship between serum GGT levels, IAC severity, and clinical outcomes in patients with acute ischemic stroke (AIS).
Methods
This cross-sectional study analyzed 754 patients (mean age: 65 ± 13.2 years) admitted with AIS to the Renmin Hospital of Wuhan University between 2017 and 2018.
The evaluation protocol included:
- Imaging: Brain CTA was performed on all patients. IAC severity was graded using a 5-point semi-quantitative scoring system across multiple cerebral arteries by two independent neurologists.
- Biochemical Assessment: Serum GGT levels and other metabolic markers (lipid profiles, homocysteine, blood glucose) were measured upon admission.
- Statistical Analysis: Logistic regression models were employed to identify independent predictors of mortality, stroke severity (NIHSS scores), and IAC scores, adjusting for potential confounders such as age, gender, smoking status, diabetes, and hypertension.
Results
The study revealed significant associations between elevated GGT levels and adverse outcomes, particularly in male patients.
Mortality and Stroke Severity
Serum GGT levels were significantly higher in patients who died compared to survivors (37.0 ± 26.8 vs 29.0 ± 21.5 U/L, p = 0.012). Logistic regression indicated that GGT independently predicted all-cause mortality in males (OR = 1.036, 95% CI: 1.014-1.060, p = 0.002). Furthermore, each standard deviation increase in serum GGT was associated with a more than twofold increase in mortality risk (OR = 2.272, 95% CI: 1.364-3.787, p = 0.002).
Partial correlation analysis, adjusting for age and gender, demonstrated a positive correlation between serum GGT and NIHSS scores at admission (r = 0.150, p = 0.001), indicating that higher GGT levels are associated with greater neurological impairment.
Intracranial Arterial Calcification
GGT levels were significantly elevated in patients with severe IAC compared to those with mild or no calcification (37.6 ± 33.6 vs 28.6 ± 19.2, p < 0.001). In male patients, GGT was an independent predictor of IAC scores (β = 0.006, 95% CI: 0.003-0.014, p = 0.005). Interestingly, these associations were not statistically significant in the female subgroup, suggesting potential gender-based differences in vascular pathology or GGT's biological role.
Discussion and Limitations
The findings suggest that GGT serves as more than a liver marker; it likely reflects systemic oxidative stress contributing to arterial "rusting" and calcification. However, several limitations must be considered:
- Study Design: The retrospective, cross-sectional nature of the study precludes establishing a causal relationship between GGT and IAC or mortality.
- Gender Disparity: The lack of significant findings in women may be due to the smaller female sample size (n=239) compared to males (n=515).
- Follow-up Period: The 60-day follow-up captures acute mortality but does not address long-term recurrence or chronic vascular decline.
- Standardization: The absence of a universal "gold standard" for IAC quantification complicates cross-study comparisons.
In conclusion, serum GGT levels are significantly associated with the risk of death and IAC severity in male AIS patients, highlighting its potential utility as a prognostic biomarker in clinical practice.
Summary updated